Free USA Shipping Over $99
Free USA Shipping Over $99
Skip to content

8 Week Summer Bod Cutting Stack

$179.90

8 Week Summer Bod Cutting Stack

Looking to take your gains to the next level? Stack 17-ProAndro™ and M1D Andro™ for a powerful combo of lean, dense muscle and maximum testosterone output. This duo supports a shredded, performance-ready physique—without the side effects—making it ideal for active, high-performing individuals.

8 Week Summer Bod Cutting Stack Highlights & Benefits

  • Cut Fat & Promote a Lean Dense Frame
  • Supports a Perfect Strength to Weight Ratio
  • Hardcore Testosterone Boosting Stack
  • Supports Strength Gains & Lean Muscle Gains

Directions

17-Pro Andro

Take 2 tablets per day in divided doses for 4 weeks.

M1D

Take 3 tablets per day in divided doses for 4 weeks

8 Week Summer Bod Cutting Stack Ingredients

17-Pro Andro

Serving Size: 1 Tablet
Servings Per Container : 60

Propriety Blend
17beta-{1-Ketoethyl}-androsta-1, 4-diene-3-one, 17a-ol 50mg
(-)-Epicatechin 90% 50mg

Other Ingredients: Microcrystanline Cellulose, Phosphatidylcholine 75%, Hydroxypropyl beta cyclodextrin (HPBCD), Phytosterols, Magnesium Stearate, Silica, FD&C Blue#2, FD&C Red#40,

M1D Andro

Serving Size: 1 Caplet
Servings per Container: 90

Proprietary Blend 100 mg

3b-hydroxy-androst-5-ene-17-one
Androsta-3,5-diene-7,17-dione
Metabolism Complex: 700 mg
Chicory (Root Extract)
L-Carnitine L-Tartrate
Cissus Quad. (Whole Plant Extract)
Stinging Nettle (Root Extract)
Phellodenron a. (Bark Extract)
Piperine
Luteolin
Other Ingredients: Magnesium stearate, silica, methyl cellulose, dicalcium phosphate, croscarmellose.

Warnings & Side Effects

Store in a cool dry place after opening. 

Blog posts

February 16, 2026 admin

What is ACP-105?

Is ACP-105 The Ultimate Recomp SARM? ACP-105 is a Selective Androgen Receptor Modulator or SARM. It was originally developed by Acadia Pharmaceuticals to help treat degenerative conditions like osteoporosis and muscle wasting. Unlike older performance enhancers ACP-105 was designed to...

Read now